Across TCGA pan-cancer cohorts, DHDH Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DHDH data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DHDH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DHDH expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BLCA, LUAD, and COAD are the cancer types where DHDH Mutation most reproducibly stratifies survival.